Canada's Multiple Myeloma Therapeutics Market was valued at $667 Mn in 2022 and is estimated to expand at a CAGR of 4.5% from 2022 to 2030 and will reach $849 Mn in 2030. One of the main reasons propelling the growth of this Market is the increasing adoption of combination therapies and technological advancements. The Market is segmented by type, drug and distribution channel. Some key players in this market are Apobiologix, Knight Therapeutics., Medexus Pharmaceuticals, Therapure Biopharma, Bloom Burton & Co., and others.
Canada's Multiple Myeloma Therapeutics Market was valued at $667 Mn in 2022 and is estimated to expand at a CAGR of 4.5% from 2022 to 2030 and will reach $849 Mn in 2030. Multiple myeloma, also known as Kahler's disease, is a type of blood cancer that mostly affects plasma cells. Chemotherapeutic medicines, corticosteroids, and immunomodulatory medications are among the most frequent types of multiple myeloma drugs. These medications promote bone healing, avoid hypercalcemia, bone fracture, spinal cord compression, and anaemia, and reduce the need for chemotherapy. Several anthracycline antibiotics and alkylating drugs, such as melphalan, doxorubicin, vincristine, and liposomal doxorubicin, are used as chemotherapy medicines. Proteasome inhibitors, such as bortezomib, and other substances, such as dexamethasone, prednisone, and thalidomide, are among the targeted therapy medications. One of the primary reasons driving market expansion is significant improvements in the healthcare industry, as well as the rising prevalence of haematological cancer.
Market Growth Drivers
There have been significant advancements in the development of new therapies for multiple myeloma in recent years, including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. These new therapies offer better efficacy and safety profiles compared to traditional chemotherapy, which is driving demand for these treatments. Combination therapies, which involve the use of two or more drugs to treat multiple myeloma, are becoming increasingly popular. These therapies have been shown to improve patient outcomes and reduce the risk of disease progression. As a result, the adoption of combination therapies is driving market growth. The aging population is at a higher risk of developing multiple myeloma, as the incidence of the disease increases with age. As the population ages, the demand for multiple myeloma therapeutics is expected to increase. Technological advancements, such as the development of new diagnostic tools and targeted therapies, are driving growth in the multiple myeloma therapeutics market. These advancements are enabling earlier diagnosis and more effective treatment of the disease.
he cost of multiple myeloma treatment can be high, particularly for newer therapies. This can create financial burdens for patients and healthcare systems, and limit access to treatment. Although new therapies are being developed, they may not be widely available to patients due to factors such as cost, limited production capacity, and slow regulatory approval processes. Reimbursement for multiple myeloma treatments can be challenging, particularly for newer therapies that are not yet covered by insurance plans. This can create barriers to access for patients who cannot afford the high out-of-pocket costs. Multiple myeloma therapies can cause significant side effects, including fatigue, nausea, and neuropathy. These side effects can impact patient quality of life and limit treatment adherence. Alternative treatments, such as stem cell transplantation, may compete with drug therapies for multiple myeloma. While drug therapies are often preferred due to their ease of administration and lower risks, alternative treatments may be preferred by some patients or physicians.
The healthcare policy and regulatory framework for the multiple myeloma therapeutics market in Canada is complex and is governed by several bodies, including Health Canada, the Canadian Agency for Drugs and Technologies in Health (CADTH), and the pan-Canadian Oncology Drug Review (pCODR). Health Canada is responsible for regulating drugs and medical devices in Canada. The agency reviews and approves new drugs before they can be marketed in the country. Health Canada also oversees post-market surveillance of drugs to ensure their safety and effectiveness.
CADTH is a non-profit organization that provides evidence-based assessments of the clinical and economic value of new drugs and medical technologies. Its assessments are used by Canadian health authorities and public payers to inform their reimbursement decisions.
pCODR is a partnership between Canadian provinces and territories to evaluate the clinical and cost-effectiveness of oncology drugs. The agency provides recommendations to public payers on whether to fund new cancer therapies based on their clinical and economic value.
The reimbursement scenario for multiple myeloma therapeutics in Canada varies depending on the province or territory in which a patient is receiving treatment. In general, reimbursement for cancer drugs is provided through publicly funded drug plans and private insurance plans.
Public drug plans in Canada typically cover the cost of cancer drugs for patients who meet certain eligibility criteria, such as having a valid provincial health card and a prescription from a licensed physician. However, the extent of coverage and reimbursement rates may vary by drug, province, and patient population. Private insurance plans may also cover the cost of cancer drugs, although the extent of coverage and reimbursement rates may vary depending on the specific plan. In recent years, the Canadian government has taken steps to improve access to cancer therapies, including the introduction of the pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug prices on behalf of public payers, and the creation of the Canadian Drug Agency (CDA), which is intended to streamline drug evaluation and reimbursement processes.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
188.8.131.52 Product Applications and Services
184.108.40.206 Recent Developments
220.127.116.11 Partnerships Ecosystem
18.104.22.168 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Distribution Channel
By End User (Revenue, USD Bn):
By Drug Class
Immunomodulatory drugs (IMiDs)
One of the most common therapies used to treat myeloma are immunomodulatory drugs, or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:
Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:
Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:
Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:
Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.
Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.
Other drug classes used to treat multiple myeloma include:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses